John Schieszer

A new combination therapy for treating advanced renal cell carcinoma (RCC) is showing promise in early clinical testing and may soon be approved the US Food and Drug Administration (FDA).

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for BI 1482694, which is an investigational third-generation, epidermal growth factor receptor (EGFR), mutant-specific tyrosine kinase inhibitor (TKI) for patients with non-small cell lung cancer (NSCLC).

Patients with renal cell carcinoma (RCC) who have not responded to prior therapy may soon have a new treatment option.

Oncologists now have a new tool for treating locally advanced basal cell carcinoma. On July 24, 2015, The US Food and Drug Administration (FDA) approved sonidegib (Odomzo) to treat patients with this type of cancer after it has recurred following surgery or radiation therapy.

Researchers are now reporting that the loss of a key gene (WAVE1) appears to be linked to a lethal form of prostate cancer.

An investigational cancer immunotherapy known as MPDL3280A (anti-PDL1) is receiving a breakthrough therapy designation from the US Food and Drug Administration (FDA) for treating non-small cell lung cancer (NSCLC).